ZGNX News and Press, Zogenix Inc. From 02/03/21

SELLAS Life Sciences (SLS) +60%.Tyme Technologies (TYME +57% as the company granted U.S. patent claims covering use of TYME-19.10X Capital Venture Acquisition (VCVCU +48% on plans to take Israeli electric-vehicle technology company REE Automotive public through a merg...

FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental impairments FINTEPLA was approved by the European Commission in December 2020 based...

I recommended OVID for OV935 but disliked OV101. In December, OVID fell drastically after OV101's failure. OV935 thesis still stands, however, the numbers are now different. This article was written after some asked for my current opinion on the stock. For further details se...

Zogenix ([[ZGNX]] -3.5%) reports preliminary 4Q Fintepla sales of about $8.1M, drug treats seizures associated with Dravet syndrome, topping the average revenue estimate of $6.2M.While it’s “still early days” in a drug launch with “a good deal of investor skep...

Total FINTEPLA ® preliminary, unaudited net product sales of approximately $8.1 million for the fourth quarter As of December 31, 2020, 492 healthcare prescribers had completed FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) certification process ...

The European Commission approves Zogenix's ([[ZGNX]] -0.8%) Fintepla (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.First EU market launch planned for Ger...

Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy EC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose sei...

Tevard Biosciences and Zogenix (ZGNX) collaborate to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.Zogenix is responsible for funding the collaboration, Tevard will receive an initial collaboration payment of $10M, of which ~$5M has...

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies CAMBRIDGE, Mass. and EMERYVILLE, Calif. , Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology compa...

New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome New d ata from investigator-initiated stud y in C...